The brand acquisition will support Pfizer India’s strategy to boost its coverage and equity in the Gastrointestinal therapy area
Pfizer has entered into an agreement with AstraZeneca, Sweden, to acquire the Neksium in India for a value of Rs 750 million. The transaction is subject to completion of requisite clearances.
Neksium has developed strong equity with prescribers in the Anti-Peptic Ulcerant space. Neksium, with the active ingredient Esomeprazole belongs to a class of pharmaceutical preparations called ‘Proton Pump Inhibitors’ (PPI) which are used effectively for reducing the acid secretion in the stomach. It is widely prescribed for the treatment of conditions across the Acid Peptic Disorders (APD) spectrum.
“The Neksium acquisition is aligned with our stated ambition of portfolio expansion through organic and inorganic growth in our focus therapy areas. With this acquisition, we will accelerate our growth and strengthen our leadership position in the Gastrointestinal (GI) therapy area,” said S Sridhar, MD, Pfizer.